
Shares of Delcath Systems Inc (NASDAQ:DCTH) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results.
The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus 8.3 months.